Trexan

Drug Overview

Trexan is a foundational and highly potent medication in the field of Dermatology and Rheumatology. Classified as an antimetabolite and a systemic immunosuppressant, it has been a gold standard for decades. While modern medicine has introduced advanced, injectable Biologics and highly specific Targeted Therapies, this medication remains a crucial, cost-effective, and highly reliable first-line systemic treatment for patients suffering from severe, widespread inflammatory skin diseases that do not respond to topical creams or light therapy.

Below are the essential details regarding this medication:

• Generic Name: Methotrexate (often abbreviated as MTX)
• US Brand Names: Trexall, Otrexup, Rasuvo, Xatmep (Note: Trexan is a widely recognized brand name in European and international markets).
• Route of Administration: Oral (tablets or liquid), Subcutaneous (an injection into the fat layer), or Intramuscular.
• FDA Approval Status: Fully FDA-approved. It has held FDA approval for decades for both oncological uses and severe autoimmune conditions, including its specific dermatological approval for severe psoriasis.

What Is It and How Does It Work? (Mechanism of Action)

Methotrexate is a structural analog of folic acid (Vitamin B9). To understand how it clears severe psoriasis and eczema, we must look at how cells replicate at the molecular level.

Every cell in the human body requires folate to produce DNA and RNA, which are necessary for cells to divide and multiply. To use the folate we consume in our diet, our cells rely on a specific enzyme called dihydrofolate reductase (DHFR).

In conditions like severe psoriasis, the immune system’s T-cells become hyperactive, and the skin cells (keratinocytes) multiply at an abnormally accelerated rate—up to ten times faster than normal skin. When a patient takes methotrexate, the drug enters these rapidly dividing cells and strongly binds to the DHFR enzyme, completely blocking its activity.

+1

By inhibiting DHFR, methotrexate cuts off the cellular supply of active folate. This halts the production of thymidylate and purine nucleotides—the building blocks of DNA. Without new DNA, the hyperactive T-cells cannot multiply to cause inflammation, and the skin cells are forced to slow down their rapid, abnormal division. The result is a profound decrease in systemic inflammation and a flattening of thick, scaly psoriatic plaques.

+1

FDA-Approved Clinical Indications

Primary Indication

• Severe, Recalcitrant, Disabling Psoriasis: Approved for the symptomatic control of severe psoriasis in adults who are not adequately responsive to other forms of therapy.
• Persistent Eczema (Atopic Dermatitis): Widely utilized by dermatologists as a highly evidence-based, off-label systemic treatment for severe, chronic eczema that fails topical management.

Other Approved Uses

• Rheumatological: Severe, active Rheumatoid Arthritis (RA) and Polyarticular Juvenile Idiopathic Arthritis (pJIA).
• Oncological: Curative or palliative management of various cancers, including Acute Lymphoblastic Leukemia (ALL), non-Hodgkin lymphoma, breast cancer, and osteosarcoma.

Dosage and Administration Protocols

CRITICAL SAFETY NOTE: For dermatological and rheumatological conditions, this medication is taken STRICTLY ONCE A WEEK, not every day. Taking this medication daily by mistake can result in fatal toxicity.

The following table outlines the standard administration protocols for adults treating severe skin conditions.

Dose Adjustments and Special Populations:

• Renal Insufficiency: Methotrexate is primarily cleared by the kidneys. The dose must be significantly reduced in patients with mild to moderate kidney impairment. It is strictly contraindicated in patients with severe renal failure (eGFR <30 mL/min).
• Hepatic Insufficiency: Highly toxic to the liver. It is contraindicated in patients with chronic liver disease, severe alcoholism, or pre-existing profound liver damage.

Clinical Efficacy and Research Results

Methotrexate remains a benchmark in dermatological research (2020-2026), frequently used as the baseline comparator in clinical trials for newer Biologics.

Current aggregate clinical data demonstrates the following:

• Psoriasis Efficacy: Approximately 40% to 45% of patients achieve a PASI 75 (a 75% reduction in psoriasis severity) after 16 weeks of continuous therapy. While slightly lower than modern Immunotherapy injections, its long-term reliability and oral accessibility make it a global staple.
• Eczema Efficacy: In treating severe atopic dermatitis, studies show that roughly 45% to 50% of patients experience a significant drop in their SCORAD (Scoring Atopic Dermatitis) index by week 12, with major improvements in sleep quality and itch reduction.
• Combination Therapy: Current research strongly supports using low-dose methotrexate in combination with newer Targeted Therapies (like infliximab or adalimumab). It prevents the patient’s body from forming anti-drug antibodies against the expensive biologics, thereby extending the clinical lifespan of the biologic therapy.

Safety Profile and Side Effects

BLACK BOX WARNING

Methotrexate carries multiple severe warnings.

• Hepatotoxicity: Can cause acute or chronic liver disease, liver fibrosis, and fatal cirrhosis.
• Myelosuppression: Can cause severe bone marrow suppression, leading to fatal drops in white blood cells, red blood cells, and platelets.
• Pregnancy: It is a profound teratogen. It causes fetal death and severe congenital abnormalities. It is strictly contraindicated in pregnant women.
• Lung Disease: Can induce potentially fatal acute pneumonitis (lung inflammation) at any time during therapy.
• Other: Fatal skin reactions, severe gastrointestinal toxicity, and fatal opportunistic infections.

Common Side Effects (>10% of patients)

• Nausea and stomach upset (often peaking 24 to 48 hours after the weekly dose).
• Fatigue or a feeling of mild illness (“methotrexate fog” on the day of administration).
• Stomatitis (painful mouth ulcers or sores).
• Mild, reversible hair shedding.

Serious Adverse Events

• Liver toxicity and cirrhosis (see Black Box Warning).
• Severe anemia, leukopenia, or thrombocytopenia.
• Interstitial pneumonitis (presenting as a dry, hacking, persistent cough and shortness of breath).

Management Strategies

• Folic Acid: Daily folic acid supplementation is the primary strategy to drastically reduce nausea, mouth sores, and liver strain.
• Dose Modification: If a patient’s white blood cell count drops dangerously low, the medication must be paused or reduced immediately.
• Toxicity Rescue: In the event of a severe, accidental overdose in a clinical setting, a specific rescue medication called Leucovorin (folinic acid) is administered intravenously to bypass the DHFR blockade and save the patient’s healthy cells.

Connection to Stem Cell and Regenerative Medicine

While methotrexate is a traditional immunosuppressant rather than a regenerative agent, it plays an absolutely critical, life-saving role in the field of stem cell medicine. During allogeneic hematopoietic stem cell transplantation (where a patient receives blood-forming stem cells from a donor to cure blood cancers), methotrexate is globally utilized as the primary prophylactic Immunotherapy against Graft-Versus-Host Disease (GVHD). By precisely suppressing the newly transplanted immune T-cells, methotrexate prevents the donor’s immune system from aggressively attacking the patient’s skin, liver, and gut, allowing the new stem cells to peacefully engraft and begin regenerating a healthy immune system.

Patient Management and Practical Recommendations

Pre-Treatment Tests

• Complete Blood Count (CBC) with differential.
• Comprehensive Metabolic Panel (CMP) focusing on liver function (AST, ALT, Albumin) and kidney function (Creatinine, eGFR).
• Baseline screening for Hepatitis B, Hepatitis C, and Tuberculosis (TB).
• A strict serum pregnancy test for women of childbearing potential.
• Baseline chest X-ray to check for underlying lung disease.

Precautions During Treatment

• Alcohol: You must completely abstain from alcohol while on this medication. Combining methotrexate and alcohol drastically accelerates irreversible liver damage.
• NSAIDs: Avoid taking over-the-counter pain relievers like ibuprofen or naproxen (NSAIDs) on the same day you take methotrexate. They can slow the kidneys’ ability to clear the drug, leading to sudden toxicity.
• Pregnancy Prevention: Both men and women must use highly reliable contraception during treatment. Women must wait at least one full ovulatory cycle (and ideally up to 3 to 6 months), and men should wait at least 3 months after stopping the drug before attempting to conceive.

Do’s and Don’ts

• DO pick one specific day of the week (e.g., “Methotrexate Monday”) to take your medication, to build a safe, unforgettable routine.
• DO take your prescribed folic acid supplements diligently to prevent side effects.
• DO contact your doctor immediately if you develop a persistent, dry cough, severe shortness of breath, or unexplained bleeding/bruising.
• DON’T ever take this medication daily for psoriasis or eczema.
• DON’T receive “live” vaccines (like the yellow fever or MMR vaccine) while your immune system is suppressed by this drug.
• DON’T ignore mouth sores; if they develop, it is often an early warning sign from your body that the dose is too high or you need more folic acid.

Legal Disclaimer

The information provided in this document is for educational and informational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical consultation, diagnosis, or treatment. Always seek the advice of your physician, dermatologist, rheumatologist, or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment plan. Never disregard professional medical advice or delay in seeking it because of something you have read here.